Marizyme Statistics
Total Valuation
Marizyme has a market cap or net worth of $6.59 million. The enterprise value is $30.14 million.
| Market Cap | 6.59M |
| Enterprise Value | 30.14M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Marizyme has 131.79 million shares outstanding. The number of shares has increased by 223.36% in one year.
| Shares Outstanding | 131.79M |
| Shares Change (YoY) | +223.36% |
| Shares Change (QoQ) | +105.87% |
| Owned by Insiders (%) | 34.96% |
| Owned by Institutions (%) | n/a |
| Float | 58.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.99 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 54.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.72 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -319.97% |
| Return on Capital (ROIC) | -149.89% |
| Revenue Per Employee | $42,284 |
| Profits Per Employee | -$5.31M |
| Employee Count | 13 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 6.03 |
Taxes
In the past 12 months, Marizyme has paid $15.19 million in taxes.
| Income Tax | 15.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.50% in the last 52 weeks. The beta is 0.34, so Marizyme's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -37.50% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.10 |
| Relative Strength Index (RSI) | 43.64 |
| Average Volume (20 Days) | 3,139 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marizyme had revenue of $549,691 and -$69.02 million in losses. Loss per share was -$1.39.
| Revenue | 549,691 |
| Gross Profit | -28,367 |
| Operating Income | -19.07M |
| Pretax Income | -69.02M |
| Net Income | -69.02M |
| EBITDA | -23.87M |
| EBIT | -24.71M |
| Loss Per Share | -$1.39 |
Balance Sheet
The company has $6,146 in cash and $23.56 million in debt, giving a net cash position of -$23.55 million or -$0.18 per share.
| Cash & Cash Equivalents | 6,146 |
| Total Debt | 23.56M |
| Net Cash | -23.55M |
| Net Cash Per Share | -$0.18 |
| Equity (Book Value) | -10.83M |
| Book Value Per Share | -0.08 |
| Working Capital | -25.11M |
Cash Flow
| Operating Cash Flow | -4.46M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.46M |
| FCF Per Share | -$0.03 |
Margins
Gross margin is -5.16%, with operating and profit margins of -3,469.56% and -12,555.89%.
| Gross Margin | -5.16% |
| Operating Margin | -3,469.56% |
| Pretax Margin | -12,555.89% |
| Profit Margin | -12,555.89% |
| EBITDA Margin | -4,342.49% |
| EBIT Margin | -4,495.33% |
| FCF Margin | -810.90% |
Dividends & Yields
Marizyme does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -223.36% |
| Shareholder Yield | -223.36% |
| Earnings Yield | -1,047.38% |
| FCF Yield | -67.64% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 27, 2018. It was a reverse split with a ratio of 1:29.
| Last Split Date | Jul 27, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:29 |
Scores
Marizyme has an Altman Z-Score of -15.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.26 |
| Piotroski F-Score | 3 |